Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Contemporary Challenges in Polycythemia Vera Management from the Perspective of Patients and Physicians
Although polycythemia vera (PV) is a chronic and incurable disease, effective management can allow most patients to maintain functional lives with near-normal life expectancy. However, there remain several inter-related factors that contribute to many ongoing challenges associated with the management of PV, which this review aims to explore. First, as a disease hallmarked by constitutive activation of the JAK/STAT pathway, PV is often accompanied by inflammatory symptoms that negatively impact quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 16, 2024 Category: Hematology Authors: Andrew T. Kuykendall, Jennifer T. Fine, Marina Kremyanskaya Source Type: research

Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in relapsed/refractory (r/r) Hodgkin lymphoma (HL). Although most patients respond to BV, only a minority will obtain a complete response (CR), and almost all patients eventually progress.Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor highly active in multiple subtypes of non-Hodgkin lymphoma; limited data exist regarding its use in HL. It irreversibly inhibits interleukin-2-inducible kinase (ITK) with Th1 based immune responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 10, 2024 Category: Hematology Authors: Matthew Mei, Ni-Chun Tsai, Joycelynne Palmer, Saro Armenian, Robert Chen, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Peter Martin, Kami Maddocks, David Bond, Alex F. Herrera Tags: Original Study Source Type: research

Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Patients with mature B cell malignancies such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) are at risk of developing secondary immunodeficiency disease (SID) owing to the underlying disease process and the use of anti-cancer treatments with immunosuppressive effects.1 Patients with mature B cell malignancies and SID are susceptible to severe, recurrent, or persistent infections that result in substantial morbidity and increased mortality, as well as a considerable economic burden. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 9, 2024 Category: Hematology Authors: Joshua Richter, Matthew S. Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K. Multani, Drishti Shah, Csaba Siffel Source Type: research

Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment – an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse.
Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We investigated whether serum free light chain (SFLC) measurements can predict renal outcome, to enable change in therapy to optimise prognosis and avoid dialysis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 6, 2024 Category: Hematology Authors: P. Joy Ho, Andrew Spencer, Peter Mollee, Christian E. Bryant, Anoop K. Enjeti, Noemi Horvath, Belinda E. Butcher, Judith Trotman, Simon Gibbs, Douglas E. Joshua Source Type: research

Real-world multicenter study of PD-1 blockade in HIV-associated classical Hodgkin lymphoma across the United States
Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 5, 2024 Category: Hematology Authors: Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Ki Tags: Original Study Source Type: research

Clinical significance of cytomegalovirus reactivation in patients with plasma cell dyscrasia who were treated with anti-CD38 monoclonal antibody: A retrospective analysis in a single institution
Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated with increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that is reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem cell transplantation in patients with PCD, cases of reactivation during anti-CD38 mAb therapy have been reported recently. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2024 Category: Hematology Authors: Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuk Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2024 Category: Hematology Source Type: research

Mantle Cell Lymphoma under the scope of personalized medicine: perspective and directions
Mantle Cell Lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnosti...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 27, 2024 Category: Hematology Authors: Lara Gallucci Figorelle, Peterson Tiago Galv ão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions | Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukaemia
Molecular measurable residual disease (MRD, e.g., by real-time quantitative polymerase chain reaction, RT-qPCR), is an integral part of response assessment in acute myeloid leukaemia (AML) with established prognostic and evolving therapeutic significance. MRD failure can occur through several pathways (namely MRD persistence at the end of treatment at a high level, MRD progression from a low level or MRD re-emergence during follow up; the latter two constitute MRD relapse as defined by the European Leukaemia Net) and is clinically actionable, with survival benefit reported in AML subgroups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 26, 2024 Category: Hematology Authors: Aditya Tedjaseputra, Nigel Russell, Richard Dillon Source Type: research

Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Immunotherapeutic strategies, specifically T-cell redirected therapies have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment se...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 21, 2024 Category: Hematology Authors: Noopur S. Raje, Adam D Cohen, Krina K Patel, Niels W.C.J. van de Donk, Joshua Richter, Jesus San-Miguel Source Type: research

SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Higher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Tags: Review Article Source Type: research

Characteristics and outcomes of patients with relapsed/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in greece
Most patients with multiple myeloma (MM) will develop disease recurrence during first-line (1L) treatment and eventually to subsequent treatments. These patients become refractory to treatment (developing relapsed/refractory MM [RRMM]), with disease severity and duration of remission worsening with each successive relapse.1, 2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Sach Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions | An Update on Higher Risk Myelodysplastic Syndromes
High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML) and therapeutic need for bone marrow transplantation. Use of blast percentage and other morphologic features to define MDS subtypes is rapidly shifting to incorporate genetics, resulting in a subset of former HR-MDS patients now being considered as AML in presence of leukemia-defining genetic alterations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Source Type: research

SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
The field of Cellular Immunotherapy has rapidly evolved over the past decade. Since the first Food and Drug Administration (FDA) approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) in 2017, the list of approvals expanded to include brexucabtagene autoleucel (Tecartus) in 2020, lisocabtagene maraleucel (Breyanzi) in 2021, idacabtagene vicleucel (Abecma) in 2021, and ciltacabtagene autoleucel (Carvykti) in 2022.1-9 In addition, cellular therapies are being studied earlier in the treatment course for patients with relapsed lymphoma and multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima Source Type: research